View all cases
UPC APP 34218/2025
- Case details
- Status—ActionProcedural applicationCategoryOther procedural
- Parties
- Claimants
- Genevant Sciences GmbHNPE
- Arbutus Biopharma CorporationOperating co.
Representatives- Markus van Gardingen
Respondents- Moderna, Inc.Operating co.
- Moderna Belgium S.R.L.Operating co.
- Moderna Denmark ApSOperating co.
- Moderna Sweden ABOperating co.
- Moderna Switzerland GmbHOperating co.
- Moderna Portugal Unipessoal LDAOperating co.
- ModernaTX, Inc.Operating co.
- Moderna Norway ASOperating co.
- Moderna Poland Sp. z o.o.Operating co.
Representatives- Ruben Laddé
- Joachim Renken
- Division
- The Hague LD
- Judges
- —
- Language
- —
- First decided
- Aug 13, 2025
How this compares
How long the court takes to reach a first decision.
| Median days to first decision | |
|---|---|
| All UPC | 124 |
| The Hague LD | Locked |
At the UPC: Genevant Sciences GmbH (9 cases)·Moderna Group (20 cases)
Start 14-day free trialAlready a user? Sign in
Related cases
Decisions
- 2025-08-13
Summary: The Hague Local Division considered Genevant/Arbutus's applications to extend deadlines for filing their reply to the defence and statement of defence in counterclaim, following delayed access to confidential information in the Moderna mRNA patent infringement proceedings.
Show the legal issues (3)
- Extension of time limits (Rule 9.3 RoP)
- Reply deadline after confidentiality order
- Counterclaim for revocation procedure
Documents
- 38747228115DCD5B0BB515C27B1E0429_en.pdf2025-08-13EN